🔬 Core ingredient research review

Science & Evidence
Cutting-edge research

We believe in the power of scientific data. The content below brings together global safety evaluations of the core ingredients in Soluna Doc products, together with representative findings published in international medical journals.

Explore Products →What Are Postbiotics?
1,200+
Published studies on LGG
300+
Clinical studies on LGG
490+
Published studies on BB-12
10+
Invention-patented strains
Data sourced from PubMed and other international medical databases

Core Ingredient Safety Assessment

Ingredient safety references based on publicly available evaluations from international bodies

🔬
EpiCor® postbiotic: authoritative evaluations
Cargill / Embria Health Sciences

EpiCor® is a patented postbiotic ingredient obtained from Saccharomyces cerevisiae through whole-cell fermentation followed by inactivation. It has been evaluated by the U.S. Food and Drug Administration (FDA), which issued a no-objection letter recognizing it as "Generally Recognized as Safe" (GRAS) (GRN 928). It is also Non-GMO Project Verified and is suitable for consumption as a food ingredient by children over 2 years old and adults.

✅ FDA GRAS · GRN 928✅ Non-GMO Project Verified✅ Fermented postbiotic
[Important] The content on this page is based on independent experimental data from international medical research on this ingredient, and is intended to share ingredient background and forward-looking nutrition knowledge. Soluna Doc postbiotic drink mix is a conventional food (not a medicine). It cannot replace foods for special medical purposes or medicines, and it does not prevent or treat any disease.

Foundational Clinical Research on the Ingredients

The excerpts below are drawn from academic databases such as PubMed and summarize what prior research has found about the same-named strains and ingredients

🦠
LGG & Children's Gut Health
Digestive health · Meta-analysis

A systematic review of 15 randomized controlled trials covering a total of 2,963 children:

In observations of relevant pediatric populations, LGG intake was associated with a shorter duration of acute diarrhea; the study data suggest a potentially positive role in helping maintain a balanced gut microbiota in children.
Szajewska H, Kołodziej M. Aliment Pharmacol Ther. 2015;41(6):563-572.
📎 PMID: 25616385 → View source study
🛡️
LGG & Respiratory Immunity Observations
Immune health · Randomized controlled

A double-blind, controlled trial conducted in day-care centers with 281 children aged 1-7:

Children who received a specific daily dose of LGG showed a downward trend in the reported frequency of respiratory discomfort. The study provides a scientific reference for the strain's use in everyday immune support.
Hojsak I, et al. Clin Nutr. 2010;29(3):312-316.
📎 PMID: 19896252 → View source study
🧬
BB-12 & Potential Support for Infants
Immune health · Randomized controlled

A long-term, prospective, double-blind controlled trial covering 109 infants and toddlers:

Data showed an upward trend in fecal secretory IgA (sIgA) levels among infants receiving BB-12. This marker is associated with mucosal immune barrier function, suggesting the strain may offer a degree of internal physiological support in early life.
Holscher HD, et al. Pediatr Res. 2012;72(2):203-209.
📎 PMID: 22580718 → View source study
❄️
EpiCor® & Seasonal Wellness
Postbiotic mechanisms · Randomized controlled

Two randomized, double-blind trials involving healthy adult volunteers:

During seasonal transitions, participants in the EpiCor group reported relatively fewer days of discomfort; some subjects showed a responsive change in serum immune markers within a short period.
Moyad MA, et al. Adv Ther. 2009;26(8):795-804.
📎 PMID: 19672568 → View source study
🌸
LGG & Early-Life Microbiota Intervention
Sensitive constitutions · Long-term follow-up

A landmark clinical study following mother-infant pairs with a relevant family history through long-term postpartum follow-up:

When mothers supplemented with LGG during the critical window, their infants showed favorable skin-health stability after birth. This paper is one of the most widely cited foundational studies in gut microbiota modulation.
Kalliomäki M, et al. Lancet. 2001;357(9262):1076-1079.
📎 PMID: 11297958 → View source study
🧪
The Biological Mechanisms of EpiCor® Metabolites
Postbiotic components · Mechanistic exploration

An integrative study combining chemical characterization with small-sample human monitoring:

The research confirmed that the ingredient is rich in beta-glucan and antioxidant compounds; in vitro work and preliminary physiological feedback indicated that its metabolites can bind to gut receptors, providing a basic rationale that even inanimate microbial components can carry nutritional significance.
Jensen GS, et al. Open Nutr J. 2008;2:68-75.
📎 PMID: 24006902 → View source study
1,200+
Published studies on LGG
300+
Clinical studies on LGG
490+
Published studies on BB-12
10+
Invention-patented strains
🏭Made by a certified high-tech enterprise
📋GB/T 29602 standard
✅SC food production license
🔬Patented strains

Scientific Data for Every Stage of Growth

Learn more about how science-backed formulas featuring LGG, BB-12 and EpiCor work together in our products.

Explore Product Details →

Scientific References

  1. U.S. FDA GRAS Notice GRN 231 — Lactobacillus rhamnosus GG.
  2. U.S. FDA GRAS Notice GRN 49 — Bifidobacterium lactis Bb-12.
  3. U.S. FDA GRAS Notice GRN 928 — EpiCor Dried Yeast Fermentate.
  4. EFSA BIOHAZ Panel. EFSA Journal. 2023;21(1):7747.
  5. Szajewska H, et al. Aliment Pharmacol Ther. 2015;41(6):563-572.
  6. Hojsak I, et al. Clin Nutr. 2010;29(3):312-316.
  7. Holscher HD, et al. Pediatr Res. 2012;72(2):203-209.
  8. Moyad MA, et al. Adv Ther. 2009;26(8):795-804.
  9. Kalliomäki M, et al. Lancet. 2001;357(9262):1076-1079.
  10. Jensen GS, et al. Open Nutr J. 2008;2:68-75.
This product is not a substitute for foods for special medical purposes, infant formula, or health supplements.